Biolinerx Ltd., of Jerusalem, reported positive preclinical results, online in PLoS One, for BL-9020, a monoclonal antibody for the treatment of type 1 diabetes. BL-9020 is designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas.